- Galectin Therapeutics (GALT +13.6%) is trading notably higher on nearly four times its average 10-day volume.
- Earlier, the company said it has received a U.S. patent on its galectin inhibitor GR-MD-02 for patients with fatty liver disease.
- The compound has a Fast Track designation and is currently in Phase 1 testing.
- "The issuance of this patent provides broad coverage in the U.S. for the use of GR-MD-02 in fatty liver disease through September 2031," CEO Peter Traber says. (PR)
Galectin Therapeutics gets fatty liver compound patent
Sep 10 2013, 15:08 ET